Revance Therapeutics, the maker of Botox competitor Daxxify, will be acquired for more than $900 million.
Crown Laboratories will buy out …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Bolt Biotherapeutics is reshuffling to cut costs and extend its cash runway to the second half of 2026. The California biotech said Tuesday afternoon that
Painting a sobering picture, a research team led by Children’s National Hospital culled years of data demonstrating that maternal mental illness is an under-recognized contributor
Facing persistent cases of hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA) during the pandemic, the infection prevention and control (IPC) team at Children’s Hospital New Orleans developed